You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

Mylan Ireland Ltd Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for MYLAN IRELAND LTD, and when can generic versions of MYLAN IRELAND LTD drugs launch?

MYLAN IRELAND LTD has five approved drugs.

There are nineteen US patents protecting MYLAN IRELAND LTD drugs.

There are sixty-four patent family members on MYLAN IRELAND LTD drugs in thirty-one countries and one supplementary protection certificate in one country.

Summary for Mylan Ireland Ltd
International Patents:64
US Patents:19
Tradenames:4
Ingredients:4
NDAs:5

Drugs and US Patents for Mylan Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-004 May 28, 2004 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes 8,034,946 ⤷  Try a Trial Y ⤷  Try a Trial
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes 8,053,448 ⤷  Try a Trial ⤷  Try a Trial
Mylan Ireland Ltd MIACALCIN calcitonin salmon INJECTABLE;INJECTION 017808-002 Mar 29, 1991 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes 7,910,608 ⤷  Try a Trial Y Y ⤷  Try a Trial
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes 11,858,898 ⤷  Try a Trial Y Y ⤷  Try a Trial
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes 10,343,995 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Mylan Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-001 Dec 7, 2001 4,818,816 ⤷  Try a Trial
Mylan Ireland Ltd MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995 5,733,569 ⤷  Try a Trial
Mylan Ireland Ltd MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995 5,759,565 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Mylan Ireland Ltd Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0084999 2002C/012 Belgium ⤷  Try a Trial PRODUCT NAME: FONDAPARINUX SODIQUE; REGISTRATION NO/DATE: EU/1/02/206/001 20020321
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.